Stephen Forman, MD

Leading Expert in Bone Marrow Transplantation, Treatment of Hematologic Malignancies and the Chimeric Antigen Receptor (CAR) T Cell-Based Immunotherapeutics 


Chair and Professor of Hematology, City of Hope


Professor of Surgery, Imperial College London

Marcin Kortylewski, PhD


Cancer scientist who co-discovered the key role of STAT3 as an inhibitor of immune activity in the tumor microenvironment. He is also an inventor of targeted, bi-functional CpG-STAT3 inhibitors for cancer immunotherapy. Dr. Kortylewski is an Associate Professor of Immuno-Oncology at City of Hope National Medical Center.

John Rossi, PhD


World-Leader in the development and clinical application of oligonucleotide therapeutics, co-Founder of Dicerna Pharmaceuticals, Calando Pharmaceuticals, and MiNA Therapeutics.

Dr. Rossi is a Professor at City of Hope National Medical Center, and the Chair of its Department of Molecular and Cellular Biology.

ImageHandler (1).jpg

Paloma Giangrande, PhD

Professor, University of Iowa
Director, Moderna Therapeutics

Oligonucleotide therapeutics expert

Sumanta Pal, MD

Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope

Scientific Advisors

Nagy Habib, MD

Clinical Scientist, Inventor and Entrepreneur. Co-Founder of MiNA Therapeutics

Medical oncologist and clinical scientist

©2018 by Proudly created with